|
⚲
|
| Keyboard |
| Keith Flaherty | |
|---|---|
| Firm | |
| Address | c/o Antares Therapeutics, Inc One Winthrop Square, Suite 400 Boston, MA 02110 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| Antares Therapeutics Inc | 021-546316 | Director | 30.0 M of 136.7 M |
||
| Strata Oncology Inc | 021-530232 | Director | 6.1 M of 10.0 M |
||
| Scorpion Therapeutics Inc | 021-518868 | Director | 125.7 M of 150.0 M |
||
| C-Reveal Therapeutics LLC | 021-383635 | Director | of 3.2 M |
||
| Scorpion Therapeutics Inc | 021-382478 | Director | 147.0 M | ||
| Strata Oncology Inc | 021-379693 | Director | 5.0 M of 10.0 M |
||
| Kinnate Biopharma Inc | 021-372487 | Director | 98.0 M of 98.0 M |
||
| Checkmate Pharmaceuticals Inc | 021-369265 | Director | 85.1 M of 100.1 M |
||
| Checkmate Pharmaceuticals Inc | 021-365710 | Director | 10.0 M of 10.0 M |
||
| Checkmate Pharmaceuticals Inc | 021-347004 | Director | 16.0 M of 16.0 M |
||
| Strata Oncology Inc | 021-312159 | Director | 11.8 M of 25.0 M |
||
| Loxo Oncology Inc | 021-217142 | Director | 23.9 M of 23.9 M |
||
| Clovis Oncology Inc | 021-207178 | Director | 192.0 M | ||